Shanghai ranks first in the world in the Important City Open Data Index of (7.13)
The "Important City Open Data Index in the World in 2021" released by Shanghai Academy of Social Sciences recently shows that Shanghai ranks first in the world for the second consecutive year in terms of a number of factors such as "establishing relevant laws and regulations", "open data to promote application" and "future potential". Shanghai Open Data Innovation and Application Competition (SODA) 2021 was launched simultaneously, which will last from July to the end of December. It will focus on the Red Centennial, smart mobility, healthcare, carbon neutrality, public safety, traffic management, culture and education, and send invitations across China and the world to solicit innovative application solutions of open data and create a big atmosphere for innovative application of open data.
Promoting high-quality development in biomedicine with digital transformation (7.16)
On the afternoon of July 15th, Zhang Ying, Vice Chairman of Shanghai Municipal Commission of Economy and Informatization, visited Sinopharm Shanghai Biomedical Co., Ltd. and Shanghai Zhenling Medical Technology Co., Ltd. (Endoscope Wizard) to investigate the digital transformation in the biomedical field.
The digital supply chain management system and traceability platform built by Sinopharm Biomedical ensure the controllable quality of the whole process through automatic collection of all data and realize the double closed loop of vaccine supply chain management and traceability. It has served many pharmaceutical enterprises, and the service system based on vaccine distribution quality and standardized operation process have been successfully copied to other provinces and cities. Based on the field of digestive endoscopy, Endoscope Wizard deeply develops functional modules such as quality control of endoscopy and auxiliary diagnosis and treatment to provide professional, accurate and intelligent services for medical workers.
Concentrate high-level talents and provide high-level science and technology supply: Li Qiang investigated some new research institutions (7.16)
Yesterday morning, Li Qiang, Secretary of CPC Shanghai Municipal Committee, pointed out when investigating some new research institutions that it is necessary to thoroughly implement General Secretary Xi Jinping's important exposition on scientific and technological innovation, With determination and perseverance, we should build and make good use of the strategic platform for scientific and technological innovation, strengthen the source function of scientific and technological innovation, gather high-level scientific and technological talents, and provide high-level scientific and technological supply, so as to make greater contributions to accelerating the construction of a globally influential scientific and technological innovation center in Shanghai and better serving the national strategic mission.
Municipal leaders Wu Qing and Zhuge Yujie, and Bao Xinhe, President of University of Science and Technology of China participated in relevant investigations.
The first "live drug" in China was approved for release, and the cell therapy products of Shanghai enterprises took the lead in achieving breakthroughs (7.20)
On the morning of July 18th, "CAR-T Cell Therapy Summit Forum and Yescarta China Launch Conference" was held at Shanghai Tower to celebrate the approval of the first cell therapy drug in China-Fosun Kate targeted human CD19 autologous CAR-T cell therapy product Axicabtagene Ciloleucel Injection (trade name: Yescarta®). Liu Ping, Vice Chairman of Shanghai Municipal Commission of Economy and Informatization, attended the forum and delivered a speech. Wu Qiang, Deputy Head of Pudong New Area, attended the forum.
Mr. Liu warmly congratulated the CAR-T Cell therapy Summit Forum and the launch of the first CAR-T cell therapy drug in China. He pointed out that accelerating the construction of a globally influential biomedical industry innovation highland and a world-class biomedical industry cluster is a major mission entrusted to Shanghai by the central government. Shanghai's cell therapy industry has obvious advantages in industrial base, clustering effect, medical resources and supervision experience. As the competent authority of biomedical industrialization in the city, Shanghai Municipal Commission of Economy and Informatization will, as always, provide good services for enterprises and support enterprises to make full use of the newly released support policies for the high-quality development of the biomedical industry in this city. We will promote institutional innovation, and establish and improve customs clearance convenience and joint supervision mechanism to facilitate enterprises to carry out import and export of special goods such as blood and biological products. It is hoped that enterprises will strengthen independent innovation, bring more products to the market, benefit patients and society, and add luster to Shanghai’s biomedical industry.
